Pravastatin Improves Remodeling and Cardiac Function After Myocardial Infarction by an Antiinflammatory Mechanism Rather than by the Induction of Angiogenesis

Annals of Thoracic Surgery

Volumn 81, Issue 6, 2006, Pages 2217-2225

  Li, Tao Sheng ^a   Takahashi, Masaya ^a   Suzuki, Ryo ^a   Kobayashi, Toshiro ^a   Ito, Hiroshi ^a   Mikamo, Akihito ^a   Hamano, Kimikazu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; COLLAGEN FIBER; CYTOKINE; INTERLEUKIN 1; PRAVASTATIN; STEM CELL FACTOR RECEPTOR; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; ECHOCARDIOGRAPHY; HEART FUNCTION; HEART INFARCTION; HEMATOPOIETIC CELL; HISTOPATHOLOGY; HYPERGLYCEMIA; HYPERLIPIDEMIA; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LYMPHOCYTIC INFILTRATION; MALE; MICROVASCULATURE; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; STEM CELL;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY WEIGHT; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELLS, CULTURED; COLLAGEN; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; ENDOTHELIUM, VASCULAR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INJECTIONS; INTERLEUKIN-1BETA; MALE; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; PRAVASTATIN; RANDOM ALLOCATION; RATS; RATS, ZUCKER; SINGLE-BLIND METHOD; TRIGLYCERIDES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR REMODELING;

EID: 33646850215     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2005.12.065     Document Type: Article

References (32)

1. Kocher A.A., Schuster M.D., Szabolcs M.J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7 (2001) 430-436
2. + stem cells play a key role in therapeutic angiogenesis induced by bone marrow cell implantation. Am J Physiol Heart Circ Physiol 285 (2003) H931-H937
3. Nishida M., Li T.S., Hirata K., Yano M., Matsuzaki M., and Hamano K. Improvement of cardiac function by bone marrow cell implantation in a rat hypoperfusion heart model. Ann Thorac Surg 75 (2003) 768-773
4. Hamano K., Nishida M., Hirata K., et al. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease. clinical trial and preliminary results. Jpn Circ J 65 (2001) 845-847
5. Strauer B.E., Brehm M., Zeus T., et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106 (2002) 1913-1918
6. Assmus B., Schachinger V., Teupe C., et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106 (2002) 3009-3017
7. Fuchs S., Satler L.F., Kornowski R., et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease. a feasibility study. J Am Coll Cardiol 41 (2003) 1721-1724
8. Perin E.C., Dohmann H.F., Borojevic R., et al. Transendocardial, autologous bone marrow cell transplantation for severe, chronic ischemic heart failure. Circulation 107 (2003) 2294-2302
9. Stamm C., Westphal B., Kleine H.D., et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 361 (2003) 45-46
10. Heeschen C., Lehmann R., Honold J., et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation 109 (2004) 1615-1622
11. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 (2003) 593-600
12. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89 (2001) E1-E7
13. Tepper O.M., Galiano R.D., Capla J.M., et al. Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106 (2002) 2781-2786
14. Kureishi Y., Luo Z., Shiojima I., et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6 (2000) 1004-1010
15. Vasa M., Fichtlscherer S., Adler K., et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103 (2001) 2885-2890
16. Llevadot J., Murasawa S., Kureishi Y., et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108 (2001) 399-405
17. Assmus B., Urbich C., Aicher A., et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 92 (2003) 1049-1055
18. Landmesser U., Engberding N., Bahlmann F.H., et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 110 (2004) 1933-1939
19. Pourati I., Kimmelstiel C., Rand W., and Karas R.H. Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J 146 (2003) 876-881
20. Johnson J., Carson K., Williams H., et al. Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse. model characterization and effects of pravastatin treatment. Circulation 111 (2005) 1422-1430
21. Laufs U., La Fata V., Plutzky J., and Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA Reductase inhibitors. Circulation 97 (1998) 1129-1135
22. Kersten J.R., Toller W.G., Tessmer J.P., Pagel P.S., and Warltier D.C. Hyperglycemia reduces coronary collateral blood flow through a nitric oxide-mediated mechanism. Am J Physiol 281 (2001) H2097-H2104
23. Zbinden S., Brunner N., Wustmann K., Billinger M., Meier B., and Seiler C. Effect of statin treatment on coronary collateral flow in patients with coronary artery disease. Heart 90 (2004) 448-449
24. Vincent L., Chen W., Hong L., et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor. contribution to its anti-angiogenic effect. FEBS Lett 495 (2001) 159-166
25. Vincent L., Soria C., Mirshahi F., et al. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol 22 (2002) 623-629
26. Horiguchi A., Sumitomo M., Asakuma J., Asano T., Asano T., and Hayakawa M. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 10 (2004) 8648-8655
27. Alber H.F., Dulak J., Frick M., et al. Atorvastatin decreases vascular endothelial growth factor in patients with coronary artery disease. J Am Coll Cardiol 39 (2002) 1951-1955
28. Weis M., Heeschen C., Glassford A.J., and Cooke J.P. Statins have biphasic effects on angiogenesis. Circulation 105 (2002) 739-745
29. Frick M., Dulak J., Cisowski J., et al. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells. Atherosclerosis 170 (2003) 229-236
30. Boodhwani M., Nakai Y., Voisine P., and Sellke F.W. High-dose atorvastatin improves hypercholesterolemic endothelial dysfunction without improving collateral-dependent myocardial perfusion. role of endostatin and vascular endothelial growth factor (abstract). Circulation 112 Suppl 2 (2005) II-376
31. Dichtl W., Dulak J., Frick M., et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 23 (2003) 58-63
32. Han K.H., Ryu J., Hong K.H., et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 111 (2005) 1439-1447